Skip to content

Key Takeaway: The FDA is seeking stakeholder input on robotic medical devices with autonomous or remote teleoperation capabilities. Developers of these technologies should consider how different degrees of autonomy and…

Key Takeaways:  Patent disputes involving imported products can become broader strategic contests across multiple forums. Patent owners can strengthen their position as the dispute progresses, defendants can use prosecution bars…

Key Takeaway: The U.S. Department of Energy’s new national battery strategy emphasizes domestic manufacturing, technological innovation, and the commercialization of advanced battery technologies. These initiatives will help accelerate battery innovation…

Key Takeaway: A patent owner’s unsuccessful eligibility argument does not necessarily make a case “exceptional” under 35 U.S.C. § 285. In a recent decision, the U.S. Court of Appeals for…

Key Takeaways: A jury awarded Aerosonic $116.9 million against Joby Aero, Inc. for breaching an NDA and misappropriating trade secrets related to air data probes. Suppliers should use NDAs that…

Key Takeaway: The USPTO has declined to expand the Federal Circuit’s Allergan safe harbor and kept the “anti-harassment” rationale alive. For biotech and pharma companies with large patent families, careful…

Key Takeaway: A specification may support claims broader than the specific examples it describes when it identifies features across the claimed genus. In Exelixis, Inc. v. MSN Laboratories Private Ltd.,…

Key Takeaway: Proposed federal legislation would eliminate the separate regulatory requirements for interchangeable biosimilars, potentially making it easier for biosimilars to compete with reference biologics. Congress is considering legislation aimed…

Key Takeaways: The Federal Circuit is considering whether § 1498(a) shields a government contractor from patent infringement liability when products manufactured under a federal procurement contract are ultimately provided to…

Key Takeaway: The USPTO continues to find companies with certain foreign-government ownership interests ineligible to pursue inter partes review (IPR). Companies involved in patent disputes should consider the ownership structure…

Older posts